Gregory Camus, PhD

Sr Research Scientist II
Gilead Sciences, Inc
Foster City, California, United States

Gilead Sciences (Employee, Shareholder)

Presentation(s):

• LB1 - Remdesivir for the Treatment of High-Risk Non-Hospitalized Individuals With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Trial

  Thursday, September 30, 2021
  5:15 PM - 5:30 PM EDT